Risk for Short-term Adverse Events in Older Emergency Department Users

Risk for Short-term Adverse Events in Older Emergency Department Users: '' Emergency Room Evaluation and Recommendation '' Cohort Study Database

This study evaluates the association between risk levels (i.e.; low, moderate and high) of Emergency Room Tool (ER2) and length of stay in older Emergency Room Tool (ER) users admitted to the medical or surgery wards of the Jewish General Hospital.

Study Overview

• Status: Active, not recruiting
• Conditions: Older People; Health Care; Health Impairment; Evaluations
• Intervention / Treatment: Other: Emergency Room Evaluation Tool (ER2)

Detailed Description

The Emergency Room Tool (ER2) assessment can be used by Emergency Department nurses taking care of older Emergency Department (ED) users on stretcher, and that ER2 moderate and high risk levels is associated with long length of stay in Emergency Department and hospital as well as hospital admissions.

• Study Type: Interventional
• Enrollment (Estimated): 5000
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montréal, Quebec, Canada, H3T 1E2
      • Jewish General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 75 years and older (Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Being 75 years and over
• An unplanned Emergency Department visit and to be on a stretcher.

Exclusion Criteria:

-Being 74 years and less

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Emergency Room Evaluation Tool (ER2); Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2).	Other: Emergency Room Evaluation Tool (ER2); Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Short-term adverse events	By using the Emergency Room Evaluation Tool( ER2), we will indirectly evaluate the length of hospital stay. The calculation will be done in days and hours.	In around 30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability of assessment tool	Patients at Emergency Room will be valuated by using the Emergency Room Evaluation Tool(ER2). Based on the ER2 results, it would be evaluated the usability of the Emergency Room screening tool.	24 hours in Emergency

Collaborators and Investigators

• Sponsor: Jewish General Hospital
• Investigators: Principal Investigator: Olivier Beauchet, MD, Jewish General Hospital

Publications and helpful links

General Publications

• Launay CP, Galery K, Vilcocq C, Afilalo M, Beauchet O. Risk for short-term undesirable outcomes in older emergency department users: Results of the ER2 observational cohort study. PLoS One. 2021 Aug 11;16(8):e0249882. doi: 10.1371/journal.pone.0249882. eCollection 2021.

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2019
• Primary Completion (Actual): December 1, 2021
• Study Completion (Estimated): January 1, 2025

Study Registration Dates

• First Submitted: May 23, 2019
• First Submitted That Met QC Criteria: May 24, 2019
• First Posted (Actual): May 28, 2019

Study Record Updates

• Last Update Posted (Actual): February 23, 2024
• Last Update Submitted That Met QC Criteria: February 22, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Emergencies
• Other Study ID Numbers: 2020-1726

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No